# GT-20029

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/GT-20029
> Markdown URL: https://mediated.wiki/source/GT-20029.md
> Source: https://en.wikipedia.org/wiki/GT-20029
> Source revision: 1315389949
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
| drug_name = 
| image = 
| width = 
| caption = 

<!-- Clinical data -->
| pronounce = 
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| licence_CA = 
| licence_EU = 
| DailyMedID = 
| licence_US = 
| pregnancy_AU = 
| pregnancy_category = 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [Topical](/source/Topical_medication)<ref name="AdisInsight" /><ref name="SacedaCorralo_2023" />
| class = [Androgen receptor degradation enhancer](/source/Androgen_receptor_degradation_enhancer)
| ATC_prefix = 
| ATC_suffix = 

<!-- Legal status -->
| legal_status = 

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| metabolites = 
| onset = 
| elimination_half-life = 
| duration_of_action = 
| excretion = 

<!-- Identifiers -->
| CAS_number = 
| CAS_supplemental = 
| PubChem = 
| PubChemSubstance = 
| IUPHAR_ligand = 
| DrugBank = 
| ChemSpiderID = 
| UNII = 
| KEGG = 
| ChEBI = 
| ChEMBL = 
| NIAID_ChemDB = 
| PDB_ligand = 
| synonyms = GT20029; AR-PROTAC

<!-- Chemical data -->
| IUPAC_name = 
| C= | H= | N= | O= 
| SMILES = 
| StdInChI = 
| StdInChIKey = 
}}

'''GT-20029''', also known as '''AR-PROTAC''', is an [androgen receptor degradation enhancer](/source/androgen_receptor_degradation_enhancer) which is under development for the treatment of [androgenetic alopecia](/source/androgenetic_alopecia) (male-pattern hair loss) and [acne](/source/acne).<ref name="AdisInsight">{{cite web | title = GT 20029 | date = 28 September 2024 | website = AdisInsight | url = https://adisinsight.springer.com/drugs/800062165 | access-date = 2 October 2025 }}</ref><ref name="Synapse">{{cite web | title = Delving into the Latest Updates on GT-20029 with Synapse | date = 16 August 2025 | website = Synapse | url = https://synapse.patsnap.com/drug/42532833634043c9ba770ad3352e3a39 | access-date = 2 October 2025 }}</ref><ref name="Han_2022">{{cite journal | vauthors = Han X, Sun Y | title = Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy | journal = Cell Reports Physical Science | volume = 3 | issue = 10 | article-number = 101062 | date = 2022 | doi = 10.1016/j.xcrp.2022.101062 | bibcode = 2022CRPS....301062H | doi-access = free | quote = Discovery of oral AR degrader GT20029 (undisclosed structures): Recently, Kintor Pharmaceutical Ltd. (Hong Kong Exchanges and Clearing Market [HKEX]: 9939) developed a topical AR degrader based on the PROTAC platform with development of an oral PROTAC drug (GT20029) targeting AR. The animal experiments showed that GT20029 is superior to other small molecule AR inhibitors. The company announced that the investigational new drug (IND) GT20029 for androgenetic alopecia and acne vulgaris indications was accepted by the National Medical Products Administration (NMPA) of China on February 2, 2021. With improved efficacy, GT20029 was reported to effectively avoids systemic exposure to mitigate the side effects of typical oral drugs. The time will tell how GT20029 performs in the clinical trials. }}</ref> It is used [topically](/source/topical_medication) in [gel](/source/gel) form.<ref name="AdisInsight" /><ref name="SacedaCorralo_2023" />

The drug acts as an [androgen receptor](/source/androgen_receptor) (AR) [proteolysis targeting chimera](/source/proteolysis_targeting_chimera) (PROTAC), facilitating the degradation of the AR via enhancement of [ubiquitin](/source/ubiquitin)-mediated [proteolysis](/source/proteolysis).<ref name="Han_2022" /><ref name="Sawar_2025">{{cite journal | vauthors = Sawar K, Mekani L, Kallabat A, Kato D, Potts GA | title = The 100 most cited articles in androgenetic alopecia: A bibliometric analysis | journal = Medicine | volume = 104 | issue = 12 | article-number = e41881 | date = March 2025 | pmid = 40128083 | pmc = 11936583 | doi = 10.1097/MD.0000000000041881 }}</ref><ref name="SacedaCorralo_2023">{{cite journal | vauthors = Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R | title = What's New in Therapy for Male Androgenetic Alopecia? | journal = American Journal of Clinical Dermatology | volume = 24 | issue = 1 | pages = 15–24 | date = January 2023 | pmid = 36169916 | doi = 10.1007/s40257-022-00730-y }}</ref><ref name="Patel_2024">{{cite journal | vauthors = Patel HA, Guo L, Feldman SR | title = The impact of current investigational drugs for acne on future treatment strategies | journal = Expert Opinion on Investigational Drugs | volume = 33 | issue = 2 | pages = 127–132 | date = February 2024 | pmid = 38369920 | doi = 10.1080/13543784.2024.2313091 }}</ref> It has been found to block the AR-mediated miniaturization of [hair follicle](/source/hair_follicle)s in [preclinical research](/source/preclinical_research).<ref name="Patel_2024" />

GT-20029 is under development by Suzhou Kintor Pharmaceuticals.<ref name="AdisInsight" /><ref name="Synapse" /> As of September 2024, it is in [phase 2](/source/Phases_of_clinical_research) [clinical trial](/source/clinical_trial)s and is advancing to [phase 3](/source/Phases_of_clinical_research) trials.<ref name="AdisInsight" /><ref name="Synapse" /><ref name="BioPharma2024">{{cite web | title = Kintor Pharma Advances to Phase III with GT20029, Pioneering Topical Treatment for Male Androgenetic Alopecia | date = 22 April 2024 | website = BioPharma APAC | url = https://biopharmaapac.com/news/31/4671/kintor-pharma-advances-to-phase-iii-with-gt20029-pioneering-topical-treatment-for-male-androgenetic-alopecia.html | access-date = 2 October 2025 }}</ref> The [chemical structure](/source/chemical_structure) of GT-20029 does not yet appear to have been disclosed.<ref name="Han_2022" />

== See also ==
* [List of investigational acne drugs](/source/List_of_investigational_acne_drugs)
* [List of investigational hair loss drugs](/source/List_of_investigational_hair_loss_drugs)
* [Pyrilutamide](/source/Pyrilutamide) (KX-826)
* [Clascoterone](/source/Clascoterone) (Winlevi; Breezula; CB-03-01)

== References ==
{{Reflist}}

{{Androgen receptor modulators}}

Category:Drugs with undisclosed chemical structures
Category:Experimental drugs
Category:Hair loss medications
Category:Nonsteroidal antiandrogens
Category:Receptor degraders
Category:Proteolysis targeting chimeras

---
Adapted from the Wikipedia article [GT-20029](https://en.wikipedia.org/wiki/GT-20029) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/GT-20029?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.